From the Guidelines
No, 5 g of compounded topical testosterone is not an appropriate dose for women. The typical starting dose of topical testosterone for women is much lower, usually ranging from 0.5 mg to 2 mg per day (which would be delivered in a much smaller amount of cream or gel, typically 0.1-0.5 g) 1. Using 5 g would likely deliver an excessive amount of testosterone, potentially causing significant side effects such as acne, hair growth in unwanted areas (hirsutism), deepening of the voice, clitoral enlargement, and menstrual irregularities. These masculinizing effects can become permanent even after stopping treatment. Additionally, high testosterone levels in women may increase cardiovascular risks and affect cholesterol levels. Some key points to consider when prescribing testosterone therapy for women include:
- The potential for adverse events, such as virilization, precocious puberty, and hyperandrogenism, especially in women and children 1
- The importance of using commercially manufactured testosterone products rather than compounded testosterone, when possible, to ensure consistent potency and quality 1
- The need for regular monitoring of hormone levels and adjustment of the dose as needed to maintain levels within the female physiological range Testosterone therapy for women should always be prescribed by a healthcare provider who can determine the appropriate dose based on blood hormone levels, symptoms, and individual health factors.
From the Research
Testosterone Dosing for Women
- The provided studies do not specifically address the dosing of 5g of compounded topical testosterone for women 2, 3, 4.
- However, one study suggests that transdermal testosterone (TDT) at a dose of 300 µg/d is effective for managing hypoactive sexual desire disorder (HSDD) in women, with minimal side effects 5.
- Another study mentions that testosterone therapy in women is a clinical challenge and emphasizes the need for safe and regulated prescribing practices 6.
Safety and Efficacy
- The studies on flibanserin, a non-hormonal treatment for HSDD, report significant improvements in sexual desire and reduced distress in premenopausal women 2, 3, 4.
- In contrast, the use of testosterone therapy in women is not as well-studied, and more research is needed to assess its safety and efficacy, particularly in the long-term 5, 6.
Current Research
- The available evidence suggests that more research is needed to determine the optimal dosing and safety of testosterone therapy in women, including the use of compounded topical testosterone 5, 6.
- Healthcare providers should follow established guidelines and practices when prescribing testosterone therapy to women, and advocate for more research and safer, regulated products 6.